A year of dismal US sales for Eli Lilly and Company's drotrecogin alpha (activated) (recombinant Protein C or Xigris) has dampened industry expectations for European success and called into question Lilly's critical care marketing strategy.
But while the odds are stacked against Lilly—the factors that observers feel may have hindered Xigris' success in the US...




